Matthew Kulke, MD
Several emerging agents are rapidly advancing the treatment paradigm for patients with neuroendocrine tumors (NETs).
, Matthew Kulke, MD, a medical oncologist at Dana-Farber Cancer Institute, discussed the evolving treatment paradigm for patients with NETs.
OncLive: What exciting advancements have occurred in the treatment of patients with NETs?
: There are several new treatments that are focused on tumor control for patients with NETs. For example, there is a phase II study of cabozantinib, a tyrosine kinase inhibitor that targets VEGF and c-MET. The study showed encouraging results, leading us to believe that cabozantinib will be taken forward into a large randomized trial that is designed as a registration study. Hopefully, we will get another new treatment for patients with NETs.
A companion study called TELECAST investigated patients who did not have severe diarrhea but showed that telotristat also helped those patients. Again, we are seeing more data on some of these new treatments that are available for our patients.
How has telotristat impacted patients’ quality of life?
[Dana-Farber Cancer Institute researchers] were involved in the registration study that led to that approval, giving us some experience with this drug. It is great to have an option for patients who have carcinoid syndrome and symptoms, especially diarrhea, despite being on somatostatin analogs, since we previously did not have many options in that scenario. This represents one effective option.
... to read the full story